Company / Current Liabilities
ENANTA PHARMACEUTICALS INC Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$48.6M
FY2025
5-year range
$29.8M / $62.8M
FY2021-FY2025
Trend
-15.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $8M in FY2016 to $63M in FY2023.
Based on SEC 10-K filings.
$49M in FY2025 with a 5-year CAGR of +15.0%.
Improved from $63M to $49M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +17.6%
- 5-Year CAGR
- +15.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +15.0%, indicating consistent growth.
- In FY2025, current liabilities decreased 15.6% year-over-year.
- Peak current liabilities was recorded in FY2023.
- Lowest current liabilities in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.6M | -15.6% |
| FY2024 | $57.5M | -8.4% |
| FY2023 | $62.8M | +110.5% |
| FY2022 | $29.8M | -17.5% |
| FY2021 | $36.2M | +49.7% |
| FY2020 | $24.2M | +6.8% |
| FY2019 | $22.6M | +41.1% |
| FY2018 | $16.0M | -23.6% |
| FY2017 | $21.0M | +166.0% |
| FY2016 | $7.9M | +17.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026